Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Cash from Financing Activities (2022 - 2025)

Stoke Therapeutics has reported Cash from Financing Activities over the past 4 years, most recently at $92.3 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 16157.22% year-over-year to $92.3 million; the TTM value through Dec 2025 reached $97.4 million, down 25.71%, while the annual FY2025 figure was $97.4 million, 25.71% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $92.3 million at Stoke Therapeutics, up from $3.1 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $120.6 million in Q2 2024 and troughed at $43000.0 in Q4 2022.
  • A 4-year average of $20.5 million and a median of $2.4 million in 2024 define the central range for Cash from Financing Activities.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 251254.17% in 2024 and later plummeted 99.54% in 2025.
  • Year by year, Cash from Financing Activities stood at $43000.0 in 2022, then surged by 16976.74% to $7.3 million in 2023, then tumbled by 92.26% to $568000.0 in 2024, then surged by 16157.22% to $92.3 million in 2025.
  • Business Quant data shows Cash from Financing Activities for STOK at $92.3 million in Q4 2025, $3.1 million in Q3 2025, and $554000.0 in Q2 2025.